The Centers for Disease Control and Prevention issued a nationwide health advisory alerting pediatricians and emergency department physicians to a sharp increase in Mycoplasma pneumoniae infections, commonly known as walking pneumonia. Comprehensive national hospital discharge data and clinical laboratory reports showed a surge in emergency department visits for pneumonia caused by Mycoplasma among young children aged 2 through 4; the share rose from 1.0% in late March 2024 to 7.2% by early October, a more than sevenfold expansion.
Historically, Mycoplasma pneumoniae has predominantly affected school-age children aged 5 to 17 and young adults in dense congregate settings like schools and universities; toddlers and preschool-age children rarely exhibited severe bacterial respiratory complications from the organism prior to the pandemic. Diagnoses among older children aged 5 to 17 also doubled from 3.6% to 7.4% over the same timeframe. Dr. Misti G. Ellsworth, an associate professor of pediatric infectious diseases at UTHealth Houston, evaluated the clinical inpatient caseload at the Texas Medical Center; Dr. Ellsworth noted that younger children frequently present with atypical clinical signs, including wheezing, sneezing, and gastrointestinal distress, and parents may mistake the bacterial illness for common viral infections such as respiratory syncytial virus (RSV) or rhinovirus.
The CDC guidance emphasized critical therapeutic distinctions for clinicians treating pediatric community-acquired pneumonia: Mycoplasma pneumoniae bacteria possess no peptidoglycan cell walls; standard first-line beta-lactam antibiotics like amoxicillin and cephalosporins are pharmacologically ineffective against the pathogen; and the advisory reminded practitioners that macrolide antibiotics such as azithromycin serve as the primary first-line therapeutic intervention, and that second-line regimens like doxycycline can be evaluated for older children.
Outpatient clinics lack rapid point-of-care antigen tests for Mycoplasma, and clinicians rely on multiplex polymerase chain reaction (PCR) respiratory swabs for confirmation; pediatric infectious disease specialists caution that post-infectious coughing frequently persists for three to six weeks.
